Chemomab Therapeutics Ltd. (CMMB): Capital Expenditures
$3.0K
Year ended 2025-12-31
-64.7%
3-year compound annual growth
-39.8%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.0K | n/a | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | $0 | -100.0% | 2026-03-23, From 2024-01-01 |
| 2023-12-31 | $3.0K | -95.6% | 2026-03-23, From 2023-01-01 |
| 2022-12-31 | $68.0K | -71.5% | 2025-04-04, From 2022-01-01 |
| 2021-12-31 | $239.0K | +528.9% | 2024-03-28, From 2021-01-01 |
| 2020-12-31 | $38.0K | n/c | 2022-03-30, From 2020-01-01 |
| 2019-12-31 | $95.0K | -55.4% | 2021-03-09, From 2019-01-01 |
| 2018-12-31 | $213.0K | n/a | 2020-03-17, From 2018-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Chemomab Therapeutics Ltd. (CMMB) | 2025-12-31 | $3.0K | n/a |
| CalciMedica, Inc. (CALC) | 2025-12-31 | $28.0K | +250.0% |
| Exicure, Inc. (XCUR) | 2025-12-31 | $1.0K | n/a |
| NRX Pharmaceuticals, Inc. (NRXP) | 2024-12-31 | $0 | -100.0% |
| PMGC Holdings Inc. (ELAB) | 2025-12-31 | $442.3K | n/m |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $5.9K | -94.4% |
| Cingulate Inc. (CING) | 2025-12-31 | $162.1K | -23.4% |
| Synlogic, Inc. (SYBX) | 2025-12-31 | $0 | -100.0% |
| Imunon, Inc. (IMNN) | 2025-12-31 | $280.6K | +849.8% |
Compare CMMB, CALC, XCUR, NRXP side by side · Screen every company in Pharmaceutical Preparations ↗